Holen Sie sich die Stockscreener-App
2.93
13.57%
0.35
Handel nachbörslich:
2.76
-0.17
-5.80%
Schlusskurs vom Vortag:
$2.58
Offen:
$3.19
24-Stunden-Volumen:
77.14M
Relative Volume:
22.34
Marktkapitalisierung:
$16.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.76M
KGV:
-36.62
EPS:
-0.08
Netto-Cashflow:
$-132.97M
1W Leistung:
+85.44%
1M Leistung:
+104.90%
6M Leistung:
-80.57%
1J Leistung:
-83.86%
1-Tages-Spanne:
$2.72
$3.45
1-Wochen-Bereich:
$1.35
$3.45
52-Wochen-Spanne:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
2.93 | 10.19M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
X4 Pharmaceuticals Stock (XFOR) Opinions on $60M Financing and Leadership Shake-Up - Quiver Quantitative
Is X4 Pharmaceuticals Nearing a Breakthrough? - StocksToTrade
X4 Pharmaceuticals’ Unexpected Surge: Buy or Hold? - timothysykes.com
Can swing trading help recover from X4 Pharmaceuticals Inc. lossesWeekly Earnings Recap & Low Drawdown Momentum Ideas - Newser
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement - Yahoo Finance
Using Bollinger Bands to evaluate X4 Pharmaceuticals Inc.2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
Reversal indicators forming on X4 Pharmaceuticals Inc. stockJuly 2025 Sentiment & Safe Entry Point Alerts - Newser
Why X4 Pharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Market Mood & AI Powered Market Entry Strategies - Newser
X4 Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Momentum & AI Powered Market Trend Analysis - Newser
Will X4 Pharmaceuticals Inc. benefit from macro trends [Weekly Investment Recap]Fast Entry Momentum Trade Alerts - Newser
X4 Pharmaceuticals Inc.’s volatility index tracking explained [Weekly Trend Recap]Technical Pattern Based Buy Signals - Newser
Real time alert setup for X4 Pharmaceuticals Inc. performanceFree Reliable Investment Entry Point Signals - Newser
XFOR’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
XFOR Stock Skyrockets: Buy Now? - StocksToTrade
X4 Pharmaceuticals Announces $60 Million Equity Financing - citybiz
XFOR’s Unexpected Surge: What’s Driving the Price? - timothysykes.com
X4 Pharma Secures $60 Mln PIPE Financing; CEO, CFO Resign; Replacements Named - Nasdaq
X4 Pharmaceuticals Inc. stock outlook for YEARCapital Secure Pattern Signal Analysis Sheet - Newser
X4 Pharmaceuticals secures $60 million in financing, appoints new leadership - Investing.com
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors - simplywall.st
X4 Pharmaceuticals Overhauls Leadership: $60M Deal Brings CTI BioPharma's $1.7B Exit Team Onboard - Stock Titan
X4 Pharmaceuticals Inc.’s volatility index tracking explainedFree Oversold Bounce Stock Play Ideas - Newser
Will X4 Pharmaceuticals Inc. benefit from macro trendsPattern Breakout Prediction for Short Term - Newser
Regression analysis insights on X4 Pharmaceuticals Inc. performanceFree Daily Top Performing Stock Insights - Newser
How X4 Pharmaceuticals Inc. stock performs during market volatilityTechnical Trend Forecast for Investors - Newser
How to use Fibonacci retracement on X4 Pharmaceuticals Inc.Low Risk Trade Timing with Analysis Metrics - Newser
Exit strategy if you’re trapped in X4 Pharmaceuticals Inc.Smart Safety Strategy With Real Data Analysis - Newser
Momentum divergence signals in X4 Pharmaceuticals Inc. chartIn-Depth Stock Trading Volume Analysis - Newser
How to integrate X4 Pharmaceuticals Inc. into portfolio analysis toolsFree Fast Entry High Potential Stock Alerts - Newser
2 Outperform Rated Small Caps with Recent Pull-backs - TradingView
Combining price and volume data for X4 Pharmaceuticals Inc.Secure Buy Strategy Based on Risk Parameters - Newser
Leading vs lagging indicators on X4 Pharmaceuticals Inc. performanceEntry Zone Forecast for Momentum Trading - Newser
Is X4 Pharmaceuticals Inc. building a consolidation baseBreakout Watcher with Entry and Exit Alerts - Newser
What analysts say about X4 Pharmaceuticals Inc. stock outlookPredictable Return Plan with Entry Guidance - Newser
Does X4 Pharmaceuticals Inc. fit your quant trading modelBuy Candidate Summary Based on Fundamentals - Newser
X4 Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
X4 Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
X4 Pharmaceuticals, Inc SEC 10-Q Report - TradingView
Fierce Biotech Layoff Tracker 2025: Tune, Bicycle let go of 25% of staff - Fierce Biotech
X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Thursday - Defense World
What makes X4 Pharmaceuticals Inc. stock price move sharplyLong-Term Stock Growth Forecast Insights - Newser
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):